• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Releases 2024 Impact Report and Introduces New Framework

    6/26/25 1:00:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email

    GREENFIELD, Ind., June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE:ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them. Reflecting on its purpose and strategic alignment, the report introduces a new framework centered on four key communities of impact, celebrating Elanco's culture of 'Going Beyond' for animals, customers, society, and our people.

    Elanco logo (PRNewsfoto/Elanco Animal Health)

    In launching a new approach to impact reporting, Elanco reaffirms its dedication to delivering lasting positive change. The report outlines eight core ambitions that shape Elanco's business and aim to generate a meaningful impact within the communities we serve worldwide.

    "Elanco is dedicated to delivering positive impact through the work we do every day, bringing innovative solutions to veterinarians, farmers, and pet owners," said Jeff Simmons, President & CEO of Elanco. "We're proud to announce a new framework that further embeds our purpose within our business operations, driving growth, accountability, and lasting positive change for society. We celebrate the progress made for these communities of impact and remain committed to advancing our objectives while delivering meaningful value to all our stakeholders."

    Key Highlights include:

    Go Beyond for Animals: Our strong portfolio, high-impact innovation, unique market approach, and dedication to making life better compels us to Go Beyond for Animals.

    • Brought key innovations to market, such as Zenrelia, Credelio Quattro, and Pradalex, driving $461 million in revenue in 2024, surpassing our innovation revenue contribution target of $420 million to $450 million.
    • Increased pet owner access to parasite protection: Ranked as #1 retail parasiticide dispensing in the U.S. while expanding global retail offerings with AdTab and the U.S. launch of Pet Protect, a new line of veterinary-formulated pet supplements under the Advantage family umbrella.
    • Donated more than $400,000 worth of products through partnerships to support animal health and wellbeing.
    • Served as an inaugural signatory to the U.S. Animal Research Openness Agreement (USARO), reinforcing Elanco's commitment to transparency in the use of animals in research.

    Go Beyond for Customers: Our promise to advocate, earn trust, and solve big challenges to create value inspires us to Go Beyond for Customers.

    • Launched Bovaer®, a first-of-its-kind methane-reducing feed ingredient for lactating dairy cattle.
    • Advanced livestock sustainability with FDA approval of three combination clearances for Experior use with MGA® in finishing heifers.
    • Enrolled 11% of the U.S. dairy herd into Elanco's UpLook database, a digital insights engine that helps farmers measure and track sustainability goals; allowing U.S. dairy farmers to earn around $10 million in net returns from monetizing carbon credit reductions using Rumensin.
    • Committed $310,000 in scholarships to support the advanced education of students entering the field of veterinary science and animal health.

    Go Beyond for Society: Our commitment to improving the health of people through animals, delivering reliable products, and safeguarding the food system drives us to Go Beyond for Society.

    • Educated nearly 150 global producers via the Elanco Food Safety Programme to tackle Salmonella outbreaks in poultry.
    • Dedicated over 730 volunteer hours in food pantries, collaborating with meal-packing organizations to pack over 115,000 meals in 2024.
    • Recovered over $7 million worth of counterfeit products and removed over 700,000 suspect online product advertisements since 2021.
    • Engaged in strategic partnership with Medgene to leverage innovative vaccine technology, including the commercialization of a Highly Pathogenic Avian Influenza (HPAI) vaccine for dairy cattle, once approved.

    Go Beyond for Our People: Our unique purpose-driven culture encourages ownership, growth, and wellbeing, motivating us to Go Beyond for Our People.

    • Achieved a 71% Employee Engagement Score as of Q1 2025, noting a 4% increase from the same period a year ago.
    • Recorded more than 26,000 volunteer hours in 2024, contributing $870,000 in estimated value of volunteerism across 1,100 global organizations.
    • Introduced a global machine safety campaign for personal health, safety, and environment (HSE), resulting in a 37% decrease in Days Away, Restricted, or Transferred (DART).
    • Successfully improved energy efficiency at the Kiel facility with an innovative HVAC system, achieving 100% renewable green electricity and 100% neutral natural gas, compensated by certification.

    Elanco invites all stakeholders to explore the full 2024 Impact Report and looks forward to further advancing our purpose of Making Life Better for animals, customers, society, and our people in everything we do.

    ABOUT ELANCO

    Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

    Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] 

    Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-releases-2024-impact-report-and-introduces-new-framework-302492454.html

    SOURCE Elanco Animal Health

    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    1/22/2026Neutral → Overweight
    Piper Sandler
    12/9/2025$30.00Overweight
    Barclays
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    11/19/2025$25.00Hold → Buy
    Argus
    10/7/2025$24.00Neutral → Overweight
    Analyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    12/9/2024$18.00Buy
    UBS
    More analyst ratings

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Modi Rajeev A. bought $95,985 worth of shares (4,500 units at $21.33), increasing direct ownership by 4% to 123,082 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:43:23 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    2/10/26 4:33:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    2/10/26 4:32:53 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    2/10/26 4:32:20 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Elanco Animal Health with a new price target

    KeyBanc Capital Markets initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $27.00

    11/21/25 8:08:36 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco Announces Updates to Board of Directors

    INDIANAPOLIS, Feb. 13, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May. Mr. Hoover is retiring from his role after joining the Board in September of 2018 as the first Chairman of the Board at the time of the company's IPO. Dr. Kochevar joined in March of 2019 as the company completed its separation from Eli Lilly and Company. "Dave Hoover's leadership was abso

    2/13/26 9:24:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement

    INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern Standard Time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-

    1/22/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST). A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for a limited time at the conclusion of the event. ABOUT ELANCOElanco

    1/6/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health Incorporated

    SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/26 1:02:28 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health Incorporated

    SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/5/26 1:23:14 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Elanco Animal Health Incorporated

    SCHEDULE 13G - Elanco Animal Health Inc (0001739104) (Subject)

    1/21/26 1:21:12 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement

    INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern Standard Time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-

    1/22/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Investor Day Defines New Era as Sustainable Growth Company

    Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x.Expects innovation revenue contribution of approximately $1.1 billion in 2026, with aims to double revenue from 'Big 6' blockbuster potential products by 2028.Discusses 10+ major innovation products in development phase with 5-6 blockbuster-potential approvals expected between 2026 and 2031. Two in-house technology development platforms

    12/9/25 7:40:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de

    10/1/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care